Authors
Dianna L Ng, Gregory M Goldgof, Brian R Shy, Andrew G Levine, Joanna Balcerek, Sagar P Bapat, John Prostko, Mary Rodgers, Kelly Coller, Sandra Pearce, Sergej Franz, Li Du, Mars Stone, Satish K Pillai, Alicia Sotomayor-Gonzalez, Venice Servellita, Claudia Sanchez San Martin, Andrea Granados, Dustin R Glasner, Lucy M Han, Kent Truong, Naomi Akagi, David N Nguyen, Neil M Neumann, Daniel Qazi, Elaine Hsu, Wei Gu, Yale A Santos, Brian Custer, Valerie Green, Phillip Williamson, Nancy K Hills, Chuanyi M Lu, Jeffrey D Whitman, Susan L Stramer, Candace Wang, Kevin Reyes, Jill MC Hakim, Kirk Sujishi, Fariba Alazzeh, Lori Pham, Edward Thornborrow, Ching-Ying Oon, Steve Miller, Theodore Kurtz, Graham Simmons, John Hackett Jr, Michael P Busch, Charles Y Chiu
Publication date
2020/9/17
Journal
Nature communications
Volume
11
Issue
1
Pages
4698
Publisher
Nature Publishing Group UK
Description
Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3–11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for …
Scholar articles
DL Ng, GM Goldgof, BR Shy, AG Levine, J Balcerek… - Nature communications, 2020
N Dianna, G Goldgof, B Shy, A Levine, J Balcerek… - MedRxiv, 2020